323990.KQ KOE
Vaxcell-Bio Therapeutics Co., Ltd.
1W: +1.8%
1M: -15.5%
3M: -12.2%
YTD: -58.0%
1Y: -54.3%
3Y: -86.2%
5Y: -94.3%
₩4,285.00 ($3.17)
-25.00 (-0.58%)
Weekly Expected Move ±7.6%
₩3630
₩3958
₩4285
₩4612
₩4940
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$66.9B
-13.0% ▼
5Y CAGR: +13.5%
Total Liabilities
$5.8B
+16.6% ▲
5Y CAGR: +47.4%
Shareholders Equity
$61.1B
-15.1% ▼
5Y CAGR: +12.0%
Cash & Investments
$25.1B
-30.4% ▼
5Y CAGR: +5.8%
Total Debt
$2.0B
-12.3% ▼
5Y CAGR: +42.4%
Net Debt
-$4.2B
+23.8% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $2.3B | $390M | $9.0B | $7.8B | $6.2B |
| Short-Term Investments | $25.0B | $20.0B | $41.0B | $28.2B | $18.9B |
| Cash & ST Investments | $27.3B | $20.4B | $50.0B | $36.1B | $25.1B |
| Net Receivables | $0 | $0 | $2K | $2.0B | $4.2B |
| Inventory | $0 | $0 | $97M | $238M | $324M |
| Other Current Assets | $353M | $210M | $582M | $15M | $137M |
| Total Current Assets | $28.2B | $20.9B | $51.2B | $39.1B | $30.0B |
| Property, Plant & Equip. | $2.8B | $2.5B | $2.7B | $6.5B | $11.6B |
| Goodwill & Intangibles | $148M | $229M | $207M | $4.8B | $7.1B |
| Long-Term Investments | -$24.9B | -$19.6B | -$10.2B | -$2.4B | $16.3B |
| Other Non-Current Assets | -$630 | $610 | $41.0B | $26.5B | $2.0B |
| Total Non-Current Assets | $3.1B | $3.3B | $33.8B | $37.8B | $36.9B |
| Total Assets | $31.3B | $24.2B | $85.0B | $76.9B | $66.9B |
| — Liabilities — | |||||
| Accounts Payable | $0 | $0 | $0 | $478M | $564M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $896M |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $179M | $202M | $195M | $418M | $2.1B |
| Total Current Liabilities | $392M | $307M | $924M | $2.8B | $3.5B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $766M | $470M | $418M | $727M | $1.2B |
| Total Non-Current Liabilities | $804M | $529M | $563M | $2.1B | $2.3B |
| Total Liabilities | $1.2B | $836M | $1.5B | $4.9B | $5.8B |
| — Equity — | |||||
| Common Stock | $7.6B | $7.6B | $11.5B | $11.5B | $11.6B |
| Retained Earnings | -$26.5B | -$33.4B | -$43.5B | -$54.4B | -$67.8B |
| Accumulated OCI | $85M | $210M | $0 | $0 | $785M |
| Total Stockholders Equity | $30.1B | $23.3B | $83.5B | $72.0B | $61.1B |
| Total Liabilities & Equity | $31.3B | $24.2B | $85.0B | $76.9B | $66.9B |
| — Key Metrics — | |||||
| Total Debt | $220M | $105M | $361M | $2.3B | $2.0B |
| Net Debt | -$2.1B | -$284M | -$8.7B | -$5.6B | -$4.2B |
| Total Investments | $110M | $431M | $30.8B | $25.8B | $35.1B |